SCHEMBL26857094

SCHEMBL26857094

Cn1cc(CNC(=O)c2cc(-c3ccc4nc(N)nn4c3)cs2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARK3 P27448 5/20 0.44
▸ MAPK1 P28482 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PIK3CG P48736 3/20 0.42
▸ PIK3CD O00329 3/20 0.42
▸ SGK1 O00141 1/20 0.42
▸ CHEK1 O14757 1/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ NUAK1 O60285 1/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ RAF1 P04049 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26857031 0.89 MAPT (0.41) MARK3MAPK1ALDH1A1MAPTPIK3CG
SCHEMBL26856882 0.86 MMP12 (0.53) MAPK1MAPTPIK3CGPIK3CDROCK2
SCHEMBL26857089 0.85 MAPK1 (0.39) MARK3MAPK1PIK3CGPIK3CDSGK1
SCHEMBL26857092 0.84 TTK (0.40) MARK3MAPK1PIK3CGPIK3CDSGK1
SCHEMBL26857153 0.84 MMP12 (0.42) MAPK1PIK3CGPIK3CDMMP12PIK3CA
SCHEMBL26857044 0.84 MMP12 (0.42) MAPK1PIK3CGPIK3CDROCK2MET
SCHEMBL26857050 0.84 MMP12 (0.47) MAPK1ALDH1A1MAPTPIK3CGPIK3CD
SCHEMBL26856951 0.84 ADORA2A (0.43) MAPK1ALDH1A1TP53PIK3CGPIK3CD
SCHEMBL26857078 0.84 ROCK1 (0.42) MAPK1PIK3CGPIK3CDROCK1MMP12
SCHEMBL26857148 0.83 MARK3 (0.46) MARK3PIK3CGPIK3CDMMP12PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PARK7 MARK3 834/4885MAPK1 3172/4885ALDH1A1 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback